Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced an ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study as part of the I-SPY 2 trial, sponsored and operated by Quantum Leap ...

AMPLIFY-201, a phase I trial evaluating treatment response to the ELI-002 vaccine, is the first study to read out using ctDNA to enroll and monitor patients with solid tumors PANDA study shows ctDNA ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of a new study in the Journal of Clinical Oncology Precision Oncology (JCO PO), ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Alliance Foundation Trials, LLC (AFT) and the Austrian Breast and Colorectal Cancer Study Group ...

Multi-cancer policy from BCBS of Louisiana covers CRC, Bladder, and IO monitoring AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today ...

Randomized study aims to reduce treatment burden for patients and utilizes Signatera to monitor for disease recurrence AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA) (NASDAQ: NTRA), a global ...

Signatera detects molecular residual disease in bladder cancer by identifying tumor DNA fragments in the bloodstream, even when not visible on scans. The IMvigor010 trial showed that Signatera-guided ...

Natera Inc. (NASDAQ: NTRA) on Wednesday revealed initial translational research results from the international randomized Phase 3 PALLAS study. Data were presented at the San Antonio Breast Cancer ...

Signatera outperformed all available risk stratification tools in postoperative and post-definitive therapy settings This recently published, real-world, multi-center, retrospective study analyzed 233 ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the activation of the NRG Oncology trial, ARCHER (NRG-GU015), a ...